Pando Bioscience Advances Enzyme Engineering Tech

The startup utilizes generative AI and high-throughput screening to accelerate the development of synthetic enzymes.

Updated on Oct. 21, 2026 in Biotech

Isometric editorial illustration of a laboratory pipette workstation, representing modern synthetic protein engineering processes. — Pando Bioscience is accelerating synthetic enzyme development by integrating generative artificial intelligence with high-throughput wet lab screening processes. AI Illustration. Upload story photo >

Live Poll

Do you believe the rapid adoption of AI in biological engineering poses more benefits than risks?

Pando Bioscience is using a platform that pairs generative AI with wet lab validation to engineer enzymes at significantly increased speeds. The company was selected as a finalist in the BioTools Innovator program in September 2026.

Why it matters

By integrating AI with high-throughput screening, the company seeks to drastically reduce the time and financial resources required to develop high-performance enzymes for various industrial applications.

The platform increases enzyme screening speeds by 1,000 times compared to traditional laboratory methods. Pando Bioscience has already successfully engineered 23 distinct enzymes across 11 different classes.

The players

Pando Bioscience

An enzyme engineering startup that utilizes generative AI to accelerate the discovery and validation of synthetic enzymes.

Will Cao

A co-founder of Pando Bioscience who completed his graduate studies at Duke University.

Yang Wang

A co-founder of Pando Bioscience who helps lead the development of the company's generative AI platform.

The details

The platform functions by assigning performance scores to various enzyme designs before validating them through physical wet laboratory experiments. This dual approach allows for the rapid iteration of synthetic proteins that would otherwise take significantly longer to develop manually.

Pando Bioscience was co-founded in 2022.
The firm was named a competition finalist in September 2026.
The BioTools Innovator 2026 Capstone Event took place on October 14, 2026.

The Tech Race

Pando Bioscience's rise highlights the broader industry shift toward using machine learning to replace manual, low-throughput experimental processes in biology. This approach positions the startup against traditional laboratory-heavy incumbents that struggle with the cost and scale of modern enzyme discovery.

The increased efficiency in enzyme engineering could eventually lead to cheaper or more effective chemical products and pharmaceutical ingredients for consumers. However, these tools are currently used by commercial firms rather than individual software users or retail customers.

The takeaway

Pando Bioscience demonstrates how artificial intelligence is transforming the speed of synthetic biology research. Investors and researchers should monitor how these AI-driven platforms impact the manufacturing costs of specialized enzymes across diverse industries.